Geode Capital Management LLC Has $60.33 Million Stock Position in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Geode Capital Management LLC raised its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 0.5% in the third quarter, according to its most recent filing with the SEC. The firm owned 1,357,531 shares of the biopharmaceutical company’s stock after purchasing an additional 6,101 shares during the quarter. Geode Capital Management LLC owned approximately 2.38% of Agios Pharmaceuticals worth $60,326,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in AGIO. Acadian Asset Management LLC bought a new stake in shares of Agios Pharmaceuticals in the 2nd quarter valued at $37,000. Quest Partners LLC acquired a new position in Agios Pharmaceuticals in the second quarter valued at $40,000. Mirae Asset Global Investments Co. Ltd. boosted its position in Agios Pharmaceuticals by 21.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock valued at $94,000 after acquiring an additional 363 shares during the last quarter. CWM LLC boosted its position in Agios Pharmaceuticals by 554.7% during the third quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock valued at $96,000 after acquiring an additional 1,836 shares during the last quarter. Finally, Quantbot Technologies LP acquired a new stake in Agios Pharmaceuticals during the 3rd quarter worth about $146,000.

Agios Pharmaceuticals Trading Down 1.1 %

Shares of AGIO stock opened at $35.42 on Friday. The firm has a fifty day simple moving average of $49.79 and a two-hundred day simple moving average of $46.65. Agios Pharmaceuticals, Inc. has a 12 month low of $20.96 and a 12 month high of $62.58. The firm has a market capitalization of $2.02 billion, a PE ratio of 3.12 and a beta of 0.80.

Insider Activity

In other news, CFO Cecilia Jones sold 2,542 shares of the firm’s stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total value of $124,634.26. Following the transaction, the chief financial officer now owns 20,158 shares in the company, valued at $988,346.74. This trade represents a 11.20 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 4.93% of the company’s stock.

Analyst Ratings Changes

AGIO has been the topic of several research analyst reports. Leerink Partnrs lowered Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, September 27th. Raymond James restated an “outperform” rating and set a $51.00 price target on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. Royal Bank of Canada raised their price objective on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 10th. StockNews.com upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, November 9th. Finally, Scotiabank raised their price target on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the stock a “sector outperform” rating in a report on Monday, December 9th. Five equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, Agios Pharmaceuticals currently has an average rating of “Hold” and an average price target of $56.33.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.